Hajime Tanaka

Dr. Hajime Tanaka

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SYSoichiro Yoshida
Soichiro Yoshida
Fumitaka KogaFumitaka Koga
Fumitaka Koga
SKShuichiro Kobayashi
Shuichiro Kobayashi
CIChikako Ishii
Chikako Ishii
HTHiroshi Tanaka
Hiroshi Tanaka
KKKazunori Kihara
Kazunori Kihara

1 November 2018 in RadioGraphics
Verified
Journal Article
Closed access
RWRyan D. Ward
Ryan D. Ward
HTHajime Tanaka
Hajime Tanaka
SCSteven C. Campbell
Steven C. Campbell
ERErick M. Remer
Erick M. Remer
Updated evaluation and management guidelines for localized renal cancer emphasize preserving strong oncologic outcomes while optimizing renal function; radiologists play a central role in tumor evaluation, patient counseling, and selective treatment approaches. Renal cell carcinoma (RCC) is a common cancer that is increasing in incidence because of the increased prevalence of risk factors, including tobacco use, hypertension, and obesity, and the improved detection of these tumors due to increased use of imaging. Localized renal cancer now accounts for more than 60%–70% of new RCC cases. Renal masses suggestive of cancer include enhancing solid renal lesions and Bosniak III and IV complex cystic lesions. Most of these tumors are detected incidentally, and many are slow growing with little propensity to metastasize. Radiologists have a vital role in evaluation of these tumors and subsequent patient counseling. Options for managing RCC include radical nephrectomy (RN), partial nephrectomy (PN), thermal ablation, and active surveillance. However, historically, the use of these strategies has varied among practices. Improved understanding of the biologic features of these tumors and data indicating the heterogeneous clinical course of many clinically localized renal...

4 August 2011 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
HTHajime Tanaka
Hajime Tanaka
SYSoichiro Yoshida
Soichiro Yoshida
Yasuhisa FujiiYasuhisa Fujii
Yasuhisa Fujii
CIChikako Ishii
Chikako Ishii
HTHiroshi Tanaka
Hiroshi Tanaka
KKKazunori Kihara
Kazunori Kihara


23 January 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
YYYunlin Ye
Yunlin Ye
HTHajime Tanaka
Hajime Tanaka
YWYanbo Wang
Yanbo Wang
RCRebecca A. Campbell
Rebecca A. Campbell
DPDiego Aguilar Palacios
Diego Aguilar Palacios
SCSteven C. Campbell
Steven C. Campbell

4 June 2015 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
HTHajime Tanaka
Hajime Tanaka
SYSoichiro Yoshida
Soichiro Yoshida
YKYoshinobu Komai
Yoshinobu Komai
YSYasuyuki Sakai
Yasuyuki Sakai
SUShinji Urakami
Shinji Urakami
KKKazunori Kihara
Kazunori Kihara
Objective: To determine the diagnostic accuracy of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for detecting metastasis and its impact on patient management with upper tract urothelial carcinoma (UTUC). Patients and Methods: Consecutive patients with UTUC underwent 18F-FDG PET/CT after CT for initial staging (n = 47) and for restaging at recurrence (n = 9). Diagnostic accuracy for detecting metastases with PET/CT and CT was compared statistically. The impact of PET/CT on patient management was assessed by comparing questionnaires that were completed by the attending physicians before and after PET/CT. Results: In the lesion-based analysis, 142 lesions were diagnosed as metastases. The sensitivity of PET/CT was significantly better than that of CT (85 vs. 50%, p = 0.0001). In the patient-based analysis, 22 patients were diagnosed as having metastases. The sensitivity/specificity/accuracy of PET/CT tended to be superior to those of CT, but these values were not significantly different (95, 91, and 93% vs. 82, 85, and 84%; p = 0.25, 0.50, and 0.063, respectively). The clinicians changed their assessments of disease extent and management plans in 18 (32%) and 11 (20%) patients, respectively, based on the PET/CT results. Conclusions: The diagnostic accuracy of PET/CT for detecting metastasis was superior to that of CT. PET/CT provided additional information to the CT-based staging, which had an impact on patient management.